Home/Nkarta/Cynthia M. Butitta

CM

Cynthia M. Butitta

Board Member

Therapeutic Areas

Oncology Autoimmune Diseases

Nkarta Pipeline

Drug	Indication	Phase
NKX019	Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)	Phase 1
NKX101	Relapsed/Refractory Acute Myeloid Leukemia (AML) / Higher-Risk Myelodysplastic Syndromes (MDS)	Phase 1

Leadership Team at Nkarta

Paul J. Hastings

President, Chief Executive Officer, and Chairman of the Board

James R. Trager, Ph.D.

Chief Scientific Officer

Nigel R. Parker, Ph.D.

Chief Financial Officer

David R. Shook, M.D.

Chief Medical Officer

Randy A. Maddux

Chief Operating Officer

Stephen J. Kelsey, M.D., FRCP, FRCPath

Former Chief Medical Officer

Rajesh K. Malik, M.D.

Board Member, Partner at Samsara BioCapital

David W. Meline

Board Member, former CFO of Amgen

Lewis L. Lanier, Ph.D.

Scientific Advisory Board, Professor at UCSF

View full Nkarta profile